A little over two years after Lyndra Therapies Inc. initially revealed its innovation for time-delayed drug delivery through an easy tablet, the company has actually raised $55 million to continue establishing the technology for public usage.
By producing a new type of ultra long-acting drug-delivery mechanism in pills, the company claims it can get rid of the requirement for clients to follow stringent standards for taking their medication.
Following physicians’ prescriptions for medication is an issue in emerging markets and among elderly patients, and the brand-new innovation has ramifications for treating practically whatever.
Established in the Massachusetts Institute of Technology lab of Dr. Robert Langer, Lyndra was co-founded by Langer and Amy Schulman, a former legal representative for the pharmaceutical market and a partner recruited to run the LS Polaris Innovation fund established by Polaris Partners in 2014 to buy health care companies.
Polaris led the company’s most current round of funding, which likewise consisted of brand-new investors like the Chinese personal equity giant HOPU Investments, Gilead Sciences, Invus, Orient Life and the Costs & Melinda Gates Structure (which at first offered funding for Dr. Langer’s research study out of MIT).
Lyndra has actually raised the cash as it continues along the path toward establishing a tablet to deal with schizophrenia. Phase II trials for the tablet, which are needed prior to it can be approved by U.S. regulators, are expected to begin next year. The business said it also will be establishing other drug candidates that are developed internally and through collaborations over the coming years.
” Lyndra’s long-acting treatments have the prospective to deal with a variety of disease states,” said Robert Langer, co-founder and Board Member of Lyndra Therapeutics. “The capability to move from daily to weekly administration of an oral drug is groundbreaking. I think Lyndra’s long-acting oral pill will be really transformative.”
For investors like the Gates Foundation it was the company’s early work around anti-malarial drugs and HIV that likely brought in attention.
When the company initially revealed its innovation back in 2016, publications like The Guardian hailed it as an advancement in drug shipment.
The technology depends in part on the unique structure of the pill itself. Encapsulated within an absorbable pill is a star-shaped structure that has 6 arms folded in on itself. As stomach acid liquifies the casing for the tablet the arms unfold and release their payload in time. As the star unfolds it expands in size so it can stay in the stomach instead of being pressed down the gastrointestinal system. Ultimately the arms break off and the staying pieces of the pill are naturally expelled– like undigested food.
” Individuals worldwide depend on medications that need taking a pill every single day and even multiple times a day,” stated Amy Schulman, a co-founder of Lyndra and its CEO, when the technology was very first revealed. “That roughly 50 percent of patients in the developed world do not take their medications as prescribed, a figure that is a lot more difficult in the developing world, has a demonstrable impact on healthcare results and an expense approximates to the U.S. healthcare system alone of over $100 billion yearly. Lyndra’s long-acting technology must make a real damage in this protracted issue and help change the lives of millions of patients who feel connected to the everyday tablet.”